Dashboard
Manage Tickers

BYSI BeyondSpring Inc.

Nasdaq beyondspringpharma.com


$ 2.01 $ -0.16 (-7.27 %)    

Wednesday, 22-Oct-2025 15:59:50 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.27 $ -5.89 (-0.96 %)
DIA $ 464.98 $ -3.44 (-0.73 %)
SPY $ 666.76 $ -3.49 (-0.52 %)
TLT $ 92.19 $ 0.06 (0.07 %)
GLD $ 376.01 $ 0.04 (0.01 %)
$ 2.04
$ 2.34
$ 1.07 x 100
$ 2.40 x 2
$ 1.99 - $ 2.40
$ 0.98 - $ 3.44
67,628
na
82.28M
$ 0.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
10/22/2025 21:06:21

beyondspring-q2-eps-004-up-from-010-yoy
BeyondSpring Q2 EPS $(0.04) Up From $(0.10...
08/13/2025 12:04:16

BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.04) per share. This is a 60 percent increase over losses of $(0.10)...

beyondspring-drug-triggers-immune-response-in-patients-who-failed-prior-cancer-immunotherapy
BeyondSpring Drug Triggers Immune Response...
07/07/2025 11:04:20

BeyondSpring Inc. (NASDAQ:BYSI) today announced publication of a human clinical study in Med (Cell Press) demonstrating that Pl...

beyondspring-presents-interim-phase-2-data-on-303-study-with-financial-support-from-mercks-investigator-studies-program-and-provision-of-study-drug-at-2025-asco-annual-meeting
BeyondSpring Presents Interim Phase 2 Data...
06/03/2025 11:09:35

Median PFS at 6.8 months, Disease Control Rate of 77.3%, 15 months OS% at 78% in Metastatic NSCLC Patients after Progression on...

update-beyondspring-q1-eps-006-down-from-005-yoy
UPDATE: BeyondSpring Q1 EPS $(0.06) Down F...
05/12/2025 22:19:51

BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.06) per share. This is a 20 percent decrease over losses of $(0.05)...

beyondspring-to-sell-stake-in-seed-therapeutics-for-354m
BeyondSpring To Sell Stake In SEED Therape...
01/28/2025 12:09:34

beyondspring-reports-phase-2-results-for-triple-io-combo-of-pembrolizumab-plinabulin-and-docetaxel-in-metastatic-nsclc-at-sitc-2024-211-orr-and-86-month-median-pfs-observed
BeyondSpring Reports Phase 2 Results For T...
11/11/2024 13:20:11

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
10/03/2024 16:30:59

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
10/01/2024 16:31:04

beyondspring-presented-final-data-on-dublin-3-study-2l3l-egfr-wild-type-nsclc-focusing-on-safety-outcomes-at-european-society-for-medical-oncology
Beyondspring Presented Final Data On Dubli...
09/16/2024 11:16:46

Docetaxel remains the standard of care for patients with 2L/3L NSCLC without targetable alterations despite severe neutropenia ...

beyondspring-presents-final-phase-3-results-for-plinabulin-in-2l3l-nsclc-at-islac-2024-with-concurrent-publication-in-the-lancet-respiratory-medicine
BeyondSpring Presents Final Phase 3 Result...
09/10/2024 11:44:29

Statistically Significant and Clinically Meaningful Efficacy Data with Favorable Benefit/Risk ratio from DUBLIN-3 Phase 3 Stu...

beyondspring-says-it-will-host-virtual-rd-day-to-discuss-new-plinabulin-development-strategy-for-cancer-and-updates-for-seed-therapeutics
BeyondSpring Says It Will Host Virtual R&D...
05/03/2024 11:24:24

beyondspring-reports-fy23-loss-per-share-of-054-vs-085-last-year
BeyondSpring Reports FY23 Loss Per Share O...
04/29/2024 21:35:49

As of December 31, 2023, the Company had cash, cash equivalents, restricted cash, and short-term investments of $17.9 million. ...

beyondspring-doses-first-patient-with-pembrolizumab-plinabulin-plus-etoposideplatinum-in-a-phase-2-investigator-initiated-study-of-first-line-extensive-stage-small-cell-lung-cancer
BeyondSpring Doses First Patient With Pemb...
03/25/2024 11:09:38

Current treatment for first-line ES-SCLC includes EP and EP plus PD-L1 antibodies. Although the objective response rate (ORR) i...

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
03/07/2024 17:31:22

why-united-natural-foods-shares-are-trading-lower-by-15-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why United Natural Foods Shares Are Tradin...
03/06/2024 18:54:52

Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
03/06/2024 13:07:59

why-sophia-genetics-shares-are-trading-lower-by-19-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why SOPHiA GENETICS Shares Are Trading Low...
03/05/2024 18:11:47

Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expect...

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
03/05/2024 17:33:15

beyondspring-regains-compliance-with-nasdaq-minimum-bid-price-and-periodic-filing-requirements
BeyondSpring Regains Compliance With Nasda...
02/26/2024 13:04:47

BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical co...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION